Dose and schedule
RUBY
Advanced or recurrent endometrial cancer
Advanced or recurrent endometrial cancer
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Phase 1: 6 cycles | |||
| Dostarlimab | 500 mg | IV | Day 1 |
| Carboplatin | AUC 5 | IV | Day 1 |
| Paclitaxel | 175 mg/m² | IV | Day 1 |
| Phase 2 | |||
| Dostarlimab | 1000 mg | IV | Every 6 weeks |
Evidence: RUBY (ENGOT-EN6/GOG-3031) (2023)
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Premedication and supportive care
- Paclitaxel premedication; three-drug antiemetics for carboplatin AUC 5.
- Tumour MMR status before starting (checklist).
Monitoring and dose adjustment
- TSH, glucose, liver enzymes and creatinine at baseline and before each cycle; immune-related toxicity as in the immunotherapy toxicity lesson.
Main evidence
Show detailsHide
Related cancer types
Treatment regimens (physicians)
References
2 referencesShow all references, 1 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2JEMPERLI (DOSTARLIMAB) — Prescribing Information
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/dostarlimab-carboplatin-paclitaxel-endometrial/